Merck & Co. will pay $12 million up front to license an anti-inflammatory drug program from Exelixis Inc. — a deal that ultimately could be worth up to $251 million.
The PI3K-delta program, led by the preclinical drug XL-499, targets transfer enzymes, known as kinases, that are expressed in immune system cells. When PI3K-delta is activated incorrectly, researchers believe, it contributes to inflammatory and allergic disorders, such as rheumatoid arthritis and allergic asthma.
No comments:
Post a Comment